Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.

CONCLUSIONS: Among biologics-treated patients with PsO, UST 90 mg appears to be used in patients with greater weight, baseline severity and prior biologics experience than ADA, ETA or UST 45 mg. UST 90 mg is used in patients with more comorbidities than other treatments except ADA. PMID: 26558924 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26558924?dopt=Abstract

Source: Journal of Dermatological Treatment - February 16, 2016 Category: Dermatology Tags: J Dermatolog Treat Source Type: research